Detalhe da pesquisa
1.
Therapeutic drug monitoring of nevirapine in resource-limited settings.
Clin Infect Dis
; 47(10): 1339-44, 2008 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18922070
2.
No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.
HIV Clin Trials
; 7(6): 285-90, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17197376
3.
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Ther Drug Monit
; 29(5): 566-70, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17898645
4.
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
J Acquir Immune Defic Syndr
; 41(1): 37-43, 2006 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16340471
5.
TDM: therapeutic drug measuring or therapeutic drug monitoring?
Ther Drug Monit
; 27(4): 412-6, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16044095
6.
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.
J Acquir Immune Defic Syndr
; 39(4): 419-21, 2005 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16010163
7.
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.
J Acquir Immune Defic Syndr
; 32(3): 287-91, 2003 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12626888
8.
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin.
Ther Drug Monit
; 28(2): 286, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16628147